Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
Search
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.

News Releases

view all
    • News in Focus
        • Browse News Releases

        • All Public Company News
        • All Multimedia News
        • View All News Releases

        • Regulatory News

        • D/A/CH Regulatory News
        • UK Regulatory News
        • View All Regulatory News

    • Business & Money
        • Auto & Transportation

        • Aerospace & Defense
        • Air Freight
        • Airlines & Aviation
        • Automotive
        • Maritime & Shipbuilding
        • Railroads & Intermodal Transportation
        • Supply Chain/Logistics
        • Transportation, Trucking & Railroad
        • Travel
        • Trucking & Road Transportation
        • View All Auto & Transportation

        • Business Technology

        • Blockchain
        • Broadcast Tech
        • Computer & Electronics
        • Computer Hardware
        • Computer Software
        • Data Analytics
        • Electronic Commerce
        • Electronic Components
        • Electronic Design Automation
        • Financial Technology
        • High Tech Security
        • Internet Technology
        • Nanotechnology
        • Networks
        • Peripherals
        • Semiconductors
        • View All Business Technology

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film & Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • View All Entertain­ment & Media

        • Financial Services & Investing

        • Accounting News & Issues
        • Acquisitions, Mergers & Takeovers
        • Banking & Financial Services
        • Bankruptcy
        • Bond & Stock Ratings
        • Conference Call Announcements
        • Contracts
        • Cryptocurrency
        • Dividends
        • Earnings
        • Earnings Forecasts & Projections
        • Financing Agreements
        • Insurance
        • Investments Opinions
        • Joint Ventures
        • Mutual Funds
        • Private Placement
        • Real Estate
        • Restructuring & Recapitalisation
        • Sales Reports
        • Shareholder Activism
        • Shareholder Meetings
        • Stock Offering
        • Stock Split
        • Venture Capital
        • View All Financial Services & Investing

        • General Business

        • Awards
        • Commercial Real Estate
        • Corporate Expansion
        • Earnings
        • Environmental, Social and Governance (ESG)
        • Human Resource & Workforce Management
        • Licensing
        • New Products & Services
        • Obituaries
        • Outsourcing Businesses
        • Overseas Real Estate (non-US)
        • Personnel Announcements
        • Real Estate Transactions
        • Residential Real Estate
        • Small Business Services
        • Socially Responsible Investing
        • Surveys, Polls & Research
        • Trade Show News
        • View All General Business

    • Science & Tech
        • Consumer Technology

        • Artificial Intelligence
        • Blockchain
        • Cloud Computing/Internet of Things
        • Computer Electronics
        • Computer Hardware
        • Computer Software
        • Consumer Electronics
        • Cryptocurrency
        • Data Analytics
        • Electronic Commerce
        • Electronic Gaming
        • Financial Technology
        • Mobile Entertainment
        • Multimedia & Internet
        • Peripherals
        • Social Media
        • STEM (Science, Tech, Engineering, Math)
        • Supply Chain/Logistics
        • Wireless Communications
        • View All Consumer Technology

        • Energy & Natural Resources

        • Alternative Energies
        • Chemical
        • Electrical Utilities
        • Gas
        • General Manufacturing
        • Mining
        • Mining & Metals
        • Oil & Energy
        • Oil & Gas Discoveries
        • Utilities
        • Water Utilities
        • View All Energy & Natural Resources

        • Environ­ment

        • Conservation & Recycling
        • Environmental Issues
        • Environmental Policy
        • Environmental Products & Services
        • Green Technology
        • Natural Disasters
        • View All Environ­ment

        • Heavy Industry & Manufacturing

        • Aerospace & Defence
        • Agriculture
        • Chemical
        • Construction & Building
        • General Manufacturing
        • HVAC (Heating, Ventilation & Air-Conditioning)
        • Machinery
        • Machine Tools, Metalworking & Metallurgy
        • Mining
        • Mining & Metals
        • Paper, Forest Products & Containers
        • Precious Metals
        • Textiles
        • Tobacco
        • View All Heavy Industry & Manufacturing

        • Telecomm­unications

        • Carriers & Services
        • Mobile Entertainment
        • Networks
        • Peripherals
        • Telecommunications Equipment
        • Telecommunications Industry
        • VoIP (Voice over Internet Protocol)
        • Wireless Communications
        • View All Telecomm­unications

    • Lifestyle & Health
        • Consumer Products & Retail

        • Animals & Pets
        • Beers, Wines & Spirits
        • Beverages
        • Bridal Services
        • Cannabis
        • Cosmetics & Personal Care
        • Fashion
        • Food & Beverages
        • Furniture & Furnishings
        • Home Improvement
        • Household, Consumer & Cosmetics
        • Household Products
        • Jewellery
        • Non-Alcoholic Beverages
        • Office Products
        • Organic Food
        • Product Recalls
        • Restaurants
        • Retail
        • Supermarkets
        • Toys
        • View All Consumer Products & Retail

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film & Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • View All Entertain­ment & Media

        • Health

        • Biometrics
        • Biotechnology
        • Clinical Trials & Medical Discoveries
        • Dentistry
        • FDA Approval
        • Fitness/Wellness
        • Health Care & Hospitals
        • Health Insurance
        • Infection Control
        • International Medical Approval
        • Medical Equipment
        • Medical Pharmaceuticals
        • Mental Health
        • Pharmaceuticals
        • Supplementary Medicine
        • View All Health

        • Sports

        • General Sports
        • Outdoors, Camping & Hiking
        • Sporting Events
        • Sports Equipment & Accessories
        • View All Sports

        • Travel

        • Amusement Parks & Tourist Attractions
        • Gambling & Casinos
        • Hotels & Resorts
        • Leisure & Tourism
        • Outdoors, Camping & Hiking
        • Passenger Aviation
        • Travel Industry
        • View All Travel

    • Policy & Public Interest
        • Policy & Public Interest

        • Animal Welfare
        • Corporate Social Responsibility
        • Economic News, Trends & Analysis
        • Education
        • Environmental
        • European Government
        • Labour & Union
        • Natural Disasters
        • Not For Profit
        • Public Safety
        • View All Policy & Public Interest

    • People & Culture
        • People & Culture

        • Aboriginal, First Nations & Native American
        • African American
        • Asian American
        • Children
        • Diversity, Equity & Inclusion
        • Hispanic
        • Lesbian, Gay & Bisexual
        • Men's Interest
        • People with Disabilities
        • Religion
        • Senior Citizens
        • Veterans
        • Women
        • View All People & Culture

    • Explore Our Platform
    • Plan Campaigns
    • Create with AI
    • Distribute Press Releases
    • Report Results
    • Amplify Content
    • All Products
    • General Enquiries
    • Media Enquiries
    • Partnerships
    • Hamburger menu
    • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
    • Send a Release
      • Phone

      • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

      • ALL CONTACT INFO
      • Contact Us

        +44 (0)20 7454 5110
        from 8 AM - 5:30 PM GMT

    • Searching for your content...

      No results found. Please change your search terms and try again.

      News Releases

      view all
      Close menu
    • News
    • Products
    • Contact
      • Client Login
      • Send a Release
      • Resources
      • Journalists
      • 2 News in Focus
      • 5 Business & Money
      • 5 Science & Tech
      • 5 Lifestyle & Health
      • 1 Policy & Public Interest
      • 1 People & Culture
      • Client Login
      • Send a Release
      • Resources
      • Journalists
      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content
      • All Products
      • Client Login
      • Send a Release
      • Resources
      • Journalists
      • General Enquiries
      • Media Enquiries
      • Partnerships
      • Client Login
      • Send a Release
      • Resources
      • Journalists
      Close submenu (News in Focus) News in Focus
      • Browse News Releases
      • Regulatory News
      Close submenu (Business & Money) Business & Money
      • Auto & Transportation
      • Business Technology
      • Entertain­ment & Media
      • Financial Services & Investing
      • General Business
      Close submenu (Science & Tech) Science & Tech
      • Consumer Technology
      • Energy & Natural Resources
      • Environ­ment
      • Heavy Industry & Manufacturing
      • Telecomm­unications
      Close submenu (Lifestyle & Health) Lifestyle & Health
      • Consumer Products & Retail
      • Entertain­ment & Media
      • Health
      • Sports
      • Travel
      Close submenu (Policy & Public Interest) Policy & Public Interest
      • Policy & Public Interest
      Close submenu (People & Culture) People & Culture
      • People & Culture

      AbbVie Reports Fourth-Quarter and Full-Year 2013 Financial Results


      News provided by

      AbbVie

      31 Jan, 2014, 13:44 GMT

      Share this article

      Share this article


      - Reports Fourth-Quarter Adjusted EPS of $0.82 (GAAP EPS of $0.70); Reports Full-Year Adjusted EPS of $3.14 (GAAP EPS of $2.56)

      - Delivers Fourth-Quarter Revenue of $5.1 Billion; Global HUMIRA Sales Growth of 13.4 Percent

      - Completes Successful First Year as an Independent Company, with Strong Execution Across Commercial, Regulatory, Clinical, Operational and Financial Objectives

      - Announces Completion of Phase 3 HCV Program, Including Compelling Results From Remaining Four Phase 3 Studies (See Separate News Release Issued Today)

      - Now Expects U.S. HCV Therapy Approval in 2014

      - With Record Number of Programs Currently in Late-Stage Development, Pipeline Continues to Advance in 2014 With Numerous Data Milestones, Phase Transitions, and Regulatory Submissions for Two Major Pipeline Assets in HCV and Neuroscience

      - Issues 2014 Adjusted EPS Guidance of $3.00 to $3.10, or $2.63 to $2.73 on a GAAP Basis

      NORTH CHICAGO, Illinois, Jan. 31, 2014 /PRNewswire/ -- AbbVie (NYSE:ABBV) today announced financial results for the fourth quarter and full year ended Dec. 31, 2013.

      "We are pleased with AbbVie's performance in our first full year as an independent biopharmaceutical company," said Richard A. Gonzalez, chairman and chief executive officer, AbbVie. "We achieved all of the objectives we set forth for 2013, exceeded our original earnings guidance, and established a solid foundation for the future. We intend to build on this momentum in 2014 as we invest in our key products, advance our pipeline, and prepare for significant product launches that will drive growth in 2015 and beyond."

      Fourth-Quarter Results

      • Worldwide sales were $5.111 billion in the fourth quarter, down 1.8 percent. On an operational basis, sales decreased 1.1 percent, excluding a 0.7 percent unfavorable impact from foreign exchange rate fluctuations. Excluding sales from our lipid franchise due to the loss of exclusivity, sales increased 7.9 percent on an operational basis in the quarter.
      • Fourth-quarter sales were led by the continued strength of HUMIRA. Global HUMIRA sales increased 13.4 percent. U.S. HUMIRA sales grew 18.1 percent.
      • Fourth-quarter adjusted gross margin ratio was 77.1 percent, excluding intangible asset amortization and other specified items. The gross margin ratio under U.S. generally accepted accounting principles (GAAP) was 74.9 percent.
      • Adjusted selling, general and administrative (SG&A) expense was 26.5 percent of sales in the fourth quarter, reflecting continued investment in our growth brands. On a GAAP basis, SG&A was 28.3 percent of sales.
      • Research and development (R&D) was 15.6 percent of sales in the quarter, reflecting funding actions in support of our emerging mid- and late-stage pipeline assets and the continued pursuit of additional HUMIRA indications.
      • Net interest expense was $68 million, and the adjusted tax rate was 22.2 percent in the quarter. On a GAAP basis, the fourth-quarter tax rate was 21.6 percent.
      • Fourth-quarter diluted earnings per share were $0.70 on a GAAP basis. Adjusted diluted earnings per share, excluding intangible asset amortization expense and other specified items, were $0.82.

      Key Events from the Fourth Quarter

      • This morning, AbbVie announced completion of its Phase 3 hepatitis C virus (HCV) studies; including top-line results from four remaining registrational HCV trials: TURQUOISE-II, PEARL-II, PEARL-III, and PEARL-IV trials.

      Results from the TURQUOISE-II study, which examined treatment of HCV in 380 patients with cirrhosis, a difficult-to-treat population, showed that patients treated for 12 weeks with the AbbVie combination achieved 92 percent sustained virologic response at 12 weeks post treatment (SVR12). 96 percent of patients treated with the AbbVie regimen for 24 weeks achieved SVR12.

      The PEARL-II and PEARL-III studies evaluated the potential for ribavirin-free therapy in genotype 1b (GT1b) experienced and naive patients, respectively. PEARL-IV evaluated the potential for ribavirin-free therapy in genotype 1a (GT1a) naive patients. Results from the PEARL-II study (n=179) showed that 100 percent of the GT1b experienced patients treated with the AbbVie combination without ribavirin achieved SVR12. Patients treated with the ribavirin-containing regimen, achieved 97 percent SVR12. Results from the PEARL-III study (n=419) showed that GT1b naive patients treated with our combination, with and without ribavirin, achieved 99 percent SVR12. The PEARL-IV study (n=305) showed that even in the more difficult to treat GT1a patients, our regimen with ribavirin achieved an SVR12 rate of 97 percent and the ribavirin-free regimen produced an SVR12 rate of 90 percent.

      • During the quarter, AbbVie announced top-line Phase 3 HCV results from the SAPPHIRE-I and SAPPHIRE-II studies, which examined AbbVie's HCV regimen in naive and treatment-experienced patients. Results from the SAPPHIRE trials showed that in both naive and treatment-experienced patients, treatment with AbbVie's 3-DAA therapy plus ribavirin produced high SVR rates of 96 percent. Additionally, the regimen was well-tolerated, with discontinuations due to adverse events reported in only one percent of patients receiving the combination.
      • AbbVie recently announced the initiation of a Phase 3 clinical trial evaluating the safety and efficacy of its investigational compound, veliparib (ABT-888), when added to carboplatin, a chemotherapy, in women with early-stage, triple-negative breast cancer. The three-arm trial will compare the addition of veliparib plus carboplatin or placebo plus carboplatin to standard neoadjuvant chemotherapy. We expect Phase 3 starts for veliparib in additional cancer types in 2014.
      • AbbVie and its partner recently initiated a Phase 3 comparative clinical trial designed to evaluate the efficacy and safety of ABT-199/GDC-0199, an investigational BCL-2 (B-cell lymphoma 2) selective inhibitor, in patients with relapsed refractory chronic lymphocytic leukemia (CLL). The study will compare the combination of ABT-199/GDC-0199 and rituximab to the combination of bendamustine and rituximab. Rituximab and bendamustine are commonly used to treat patients with CLL.

      Issuing Full-Year 2014 Outlook

      AbbVie expects 2014 revenue of approximately $19 billion, excluding any potential revenue from the expected 2014 U.S. launch of our HCV therapy. AbbVie is issuing diluted earnings-per-share guidance for the full-year 2014 of $3.00 to $3.10 on an adjusted basis, or $2.63 to $2.73 on a GAAP basis. The company's 2014 adjusted diluted earnings-per-share guidance excludes $0.37 per share of intangible asset amortization expense and other specified items primarily associated with certain separation-related costs and ongoing restructuring activities.

      About AbbVie

      AbbVie is a global, research-based biopharmaceutical company formed in 2013 following separation from Abbott Laboratories. The company's mission is to use its expertise, dedicated people and unique approach to innovation to develop and market advanced therapies that address some of the world's most complex and serious diseases. AbbVie employs approximately 25,000 people worldwide and markets medicines in more than 170 countries. For further information on the company and its people, portfolio and commitments, please visit www.abbvie.com. Follow @abbvie on Twitter or view careers on our Facebook or LinkedIn page.

      Conference Call

      AbbVie will host an investor conference call today at 8:00 a.m. Central time to discuss our fourth-quarter performance. Participating on the call will be Rick Gonzalez, chairman and chief executive officer; Bill Chase, executive vice president and chief financial officer; Laura Schumacher, executive vice president, business development, external affairs and general counsel; Scott Brun, vice president of clinical development; and Larry Peepo, vice president of investor relations. The call will be webcast through AbbVie's Investor Relations Web site at www.abbvieinvestor.com. An archived edition of the call will be available after 10:00 a.m. Central time.

      Non-GAAP Financial Results

      Financial results for 2013 are presented on both a reported and a non-GAAP basis. Reported results were prepared in accordance with GAAP and include all revenue and expenses recognized during the period. Non-GAAP results adjust for certain non-cash items and for factors that are unusual or unpredictable, and exclude those costs, expenses, and other specified items presented in the reconciliation tables later in this release. AbbVie's management believes non-GAAP financial measures provide useful information to investors regarding AbbVie's results of operations and assist management, analysts, and investors in evaluating the performance of the business. Non-GAAP financial measures should be considered in addition to, and not as a substitute for, measures of financial performance prepared in accordance with GAAP. The company's 2014 financial guidance is also being provided on both a reported and a non-GAAP basis.

      Forward-Looking Statements

      Some statements in this news release may be forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. The words "believe," "expect," "anticipate," "project" and similar expressions, among others, generally identify forward-looking statements. AbbVie cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Such risks and uncertainties include, but are not limited to, challenges to intellectual property, competition from other products, difficulties inherent in the research and development process, adverse litigation or government action, and changes to laws and regulations applicable to our industry. Additional information about the economic, competitive, governmental, technological and other factors that may affect AbbVie's operations is set forth in Item 1A, "Risk Factors," in AbbVie's 2012 Annual Report on Form 10-K/A, which has been filed with the Securities and Exchange Commission. AbbVie undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.


      AbbVie Inc.

      Key Product Sales

      Quarter Ended December 31, 2013

      (Unaudited)




      % Change vs. 4Q12


      Sales (in millions)


      International

      Total


      U.S.

      Int'l.

      Total

      U.S.

      Operational

      Reported

      Operational

      Reported

      TOTAL SALES

      $2,818

      $2,293

      $5,111

      (8.2%)

      9.2%

      7.5%

      (1.1%)

      (1.8%)

      Humira

      1,667

      1,372

      3,039

      18.1

      8.0

      8.2

      13.3

      13.4

      Synagis

      --

      314

      314

      n/m

      8.4

      (1.4)

      2.9

      (6.4)

      AndroGel

      289

      --

      289

      (20.9)

               n/a

        n/a

      (20.9)

      (20.9)

      Kaletra

      63

      165

      228

      (24.0)

      0.2

      (0.9)

      (7.8)

      (8.6)

      Lupron

      156

      53

      209

      0.5

      (1.7)

      (5.0)

      (0.1)

      (1.0)

      Synthroid

      189

      --

      189

      12.8

               n/a

        n/a

      12.8

      12.8

      Sevoflurane

      23

      133

      156

      (20.9)

      6.3

      3.6

      1.3

      (0.9)

      Creon

      115

      --

      115

      9.3

               n/a

        n/a

      9.3

      9.3

      Zemplar

      57

      44

      101

      (16.8)

      14.9

      16.2

      (5.4)

      (4.9)

      Duodopa

      --

      49

      49

      n/a

      15.7

      20.1

      15.7

      20.1

      Niaspan

      31

      --

      31

      (88.9)

                n/a

        n/a

      (88.9)

      (88.9)

      TriCor/Trilipix

      29

      --

      29

      (85.4)

               n/a

        n/a

      (85.4)

      (85.4)


      Note: "Operational" growth reflects the percentage change over the prior year excluding the impact of exchange rate fluctuations.

      n/a = not applicable

      n/m = not meaningful





      AbbVie Inc.

      Key Product Sales

      Twelve Months Ended December 31, 2013

      (Unaudited)




      % Change vs. 12M12


      Sales (in millions)


      International

      Total


      U.S.

      Int'l.

      Total

      U.S.

      Operational

      Reported

      Operational

      Reported

      TOTAL SALES

      $10,181

      $8,609

      $18,790

      (2.4%)

      10.1%

      8.4%

      2.9%

      2.2%

      Humira

      5,236

      5,423

      10,659

      19.6

      11.7

      10.9

      15.4

      15.0

      AndroGel

      1,035

      --

      1,035

      (10.1)

               n/a

           n/a

      (10.1)

      (10.1)

      Kaletra

      244

      718

      962

      (12.8)

      (1.0)

      (2.1)

      (4.2)

      (5.0)

      Synagis

      --

      827

      827

      n/m

      9.2

      0.2

      7.0

      (1.8)

      Lupron

      566

      219

      785

      (0.6)

      (3.2)

      (5.0)

      (1.4)

      (1.9)

      Niaspan

      650

      --

      650

      (28.7)

               n/a

           n/a

      (28.7)

      (28.7)

      Synthroid

      622

      --

      622

      12.9

               n/a

           n/a

      12.9

      12.9

      Sevoflurane

      77

      491

      568

      (5.4)

      (3.6)

      (5.7)

      (3.8)

      (5.6)

      Creon

      412

      --

      412

      16.5

               n/a

           n/a

      16.5

      16.5

      Zemplar

      218

      171

      389

      (5.1)

      10.7

      11.7

      1.2

      1.6

      TriCor/Trilipix

      303

      --

      303

      (72.4)

               n/a

           n/a

      (72.4)

      (72.4)

      Duodopa

      --

      178

      178

      n/a

      16.4

      19.5

      16.4

      19.5


      Note: "Operational" growth reflects the percentage change over the prior year excluding the impact of exchange rate fluctuations.

      n/a = not applicable

      n/m = not meaningful





      AbbVie Inc.

      Consolidated Statements of Earnings

      Quarter and Twelve Months Ended December 31, 2013 and 2012

      (Unaudited) (In millions, except per share data)



      Fourth Quarter Ended
      December 31


      Twelve Months Ended 
      December 31


      2013


      2012


      2013


      2012

      Net sales

      $5,111


      $5,206


      $18,790


      $18,380









      Cost of products sold

      1,282


      1,265


      4,581


      4,508

      Selling, general and administrative

      1,448


      1,411


      5,352


      4,989

      Research and development

      798


      681


      2,855


      2,778

      Acquired in-process research and development

      48


      28


      338


      288

      Total operating cost and expenses

      3,576


      3,385


      13,126


      12,563









      Operating earnings

      1,535


      1,821


      5,664


      5,817









      Interest (income) expense, net

      68


      88


      278


      84

      Net foreign exchange (gain) loss

      15


      (10)


      55


      17

      Other (income) expense, net

      13


      30


      (1)


      (9)

      Earnings before income tax

      1,439


      1,713


      5,332


      5,725

      Income tax expense

      311


      173


      1,204


      450

      Net earnings

      $1,128


      $1,540


      $4,128


      $5,275









      Diluted earnings per share

      $0.70


      $0.98


      $2.56


      $3.35









      Average diluted shares outstanding     

      1,608


      1,577


      1,604


      1,577


      Note:  The computation of diluted earnings per share for the quarter and twelve months ended Dec. 31, 2013 was calculated pursuant to the two-class method which requires the allocation of net earnings between common stockholders and participating security holders.  On Jan. 1, 2013, Abbott Laboratories distributed 1,577 million shares of AbbVie common stock to Abbott's shareholders in connection with the separation of AbbVie from Abbott.  The computation of diluted earnings per share for the quarter and twelve months ended Dec. 31, 2012 was calculated using the shares distributed on Jan. 1, 2013.





      AbbVie Inc.

      Reconciliation of GAAP Reported to Non-GAAP Adjusted Information

      Quarter Ended December 31, 2013

      (Unaudited) (In millions, except per share data)


      1. Specified items impacted results as follows:



      4Q13


      Earnings

      Diluted


      Pre-tax

      After-tax

      EPS

      As reported (GAAP)

      $1,439

      $1,128

      $0.70

      Adjusted for specified items:




      Intangible asset amortization

      101

      76

      0.05

      Separation costs

      103

      66

      0.04

      Acquired IPR&D

      48

      48

      0.03

      Restructuring/Other      

      11

      7

      0.00

      As adjusted (non-GAAP)

      $1,702

      $1,325

      $0.82


      Intangible asset amortization reflects costs recognized as a result of licensing and acquisition activities.  Separation costs are expenses related to the separation of AbbVie from Abbott.  Acquired IPR&D reflects upfront payments related to previously announced collaborations.  Restructuring/Other is primarily associated with previously announced restructuring activities.





      2. The impact of the specified items by line item was as follows:





      4Q13


      Cost of products sold

      SG&A

      R&D

      Acquired IPR&D

      Other (income) expense

       As reported (GAAP)

      $1,282

      $1,448

      $798

      $48

      $13

       Adjusted for specified items:






       Intangible asset amortization

      (101)

      --

      --

      --

      --

       Separation costs

      (5)

      (95)

      (3)

      --

      --

       Acquired IPR&D

      --

      --

      --

      (48)

      --

       Restructuring/Other

      (8)

      --

      --

      --

      (3)

       As adjusted (non-GAAP)

      $1,168

      $1,353

      $795

      --

      $10





      3. The adjusted tax rate for the fourth quarter was 22.2 percent, as detailed below:



      4Q13


      Pre-tax

      Income



      income

      taxes

      Tax rate

      As reported (GAAP)

      $1,439

      $311

      21.6%

      Specified items

      263

      66

      25.1%

      As adjusted (non-GAAP)

      $1,702

      $377

      22.2%





      AbbVie Inc.

      Reconciliation of GAAP Reported to Non-GAAP Adjusted Information

      Twelve Months Ended December 31, 2013

      (Unaudited) (In millions, except per share data)


      1. Specified items impacted results as follows:



      12M13


      Earnings

      Diluted


      Pre-tax

      After-tax

      EPS

      As reported (GAAP)

      $5,332

      $4,128

      $2.56

      Adjusted for specified items:




      Intangible asset amortization

      509

      370

      0.23

      Separation costs

      255

      163

      0.10

      Acquired IPR&D

      338

      338

      0.21

      Restructuring/Other      

      81

      67

      0.04

      As adjusted (non-GAAP)

      $6,515

      $5,066

      $3.14


      Intangible asset amortization reflects costs recognized as a result of licensing and acquisition activities.  Separation costs are expenses related to the separation of AbbVie from Abbott.  Acquired IPR&D reflects upfront payments related to previously announced collaborations.  Restructuring/Other is primarily associated with previously announced restructuring activities.





      2. The impact of the specified items by line item was as follows:



      12M13


      Cost of products sold

      SG&A

      R&D

      Acquired IPR&D

      Net foreign exchange (gain) loss

      Other (income) expense

       As reported (GAAP)

      $4,581

      $5,352

      $2,855

      $338

      $55

      ($1)

       Adjusted for specified items:







       Intangible asset amortization

      (509)

      --

      --

      --

      --

      --

       Separation costs

      (16)

      (230)

      (9)

      --

      --

      --

       Acquired IPR&D

      --

      --

      --

      (338)

      --

      --

       Restructuring/Other

      (5)

      (38)

      (15)

      --

      (11)

      (12)

       As adjusted (non-GAAP)

      $4,051

      $5,084

      $2,831

      --

      44

      ($13)





      3. The adjusted tax rate for the fourth quarter was 22.2 percent, as detailed below:



      12M13


      Pre-tax

      Income



      income

      taxes

      Tax rate

      As reported (GAAP)

      $5,332

      $1,204

      22.6%

      Specified items

      1,183

      245

      20.7%

      As adjusted (non-GAAP)

      $6,515

      $1,449

      22.2%




      Modal title

      Also from this source

      AbbVie Announces TEPKINLY® (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma

      AbbVie (NYSE: ABBV) today announced that the European Commission (EC) granted marketing authorization for TEPKINLY® (epcoritamab) in combination with ...

      AbbVie Announces Positive Phase 3 Results for Epcoritamab Plus Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

      AbbVie (NYSE: ABBV) today announced topline results from the Phase 3 EPCORE DLBCL-4 trial evaluating the combination of epcoritamab, a T-cell...

      More Releases From This Source

      Explore

      Health Care & Hospitals

      Health Care & Hospitals

      Medical Pharmaceuticals

      Medical Pharmaceuticals

      Pharmaceuticals

      Pharmaceuticals

      Biotechnology

      Biotechnology

      News Releases in Similar Topics

      Contact PR Newswire

      • +44 (0)20 7454 5110
        from 8 AM - 5:30 PM GMT
      • General Enquiries
      • Media Enquiries
      • Partnerships

      Products

      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content

      About

      • About PR Newswire
      • About Cision
      • Careers
      • Accessibility Statement
      • APAC
      • APAC - Simplified Chinese
      • APAC - Traditional Chinese
      • Brazil
      • Canada
      • Czech
      • Denmark
      • Finland
      • France
      • Germany
      • India
      • Indonesia
      • Israel
      • Japan
      • Korea
      • Mexico
      • Middle East
      • Middle East - Arabic
      • Netherlands
      • Norway
      • Poland
      • Portugal
      • Russia
      • Slovakia
      • Spain
      • Sweden
      • United States
      • Vietnam

      My Services

      • All News Releases
      • PR Newswire Amplify™
      • Resources
      • Journalists
      • Data Privacy

      Do not sell or share my personal information:

      • Submit via Privacy@cision.com 
      • Call Privacy toll-free: 877-297-8921

      Contact PR Newswire

      Products

      About

      My Services
      • All News Releases
      • Customer Portal
      • Resources
      • Journalists
      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT
      • Terms of Use
      • Privacy Policy
      • Information Security Policy
      • Site Map
      • RSS
      • Cookie Settings
      Copyright © 2026 PR Newswire Europe Limited. All Rights Reserved. A Cision company.